Engasertib

Engasertib
Identifiers
  • 6-[4-(1-amino-3-hydroxycyclobutyl)phenyl]-1-ethyl-7-phenylpyrido[2,3-b][1,4]oxazin-2-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC25H25N3O3
Molar mass415.493 g·mol−1
3D model (JSmol)
  • CCN1C(=O)COC2=C1C=C(C(=N2)C3=CC=C(C=C3)C4(CC(C4)O)N)C5=CC=CC=C5
  • InChI=InChI=1S/C25H25N3O3/c1-2-28-21-12-20(16-6-4-3-5-7-16)23(27-24(21)31-15-22(28)30)17-8-10-18(11-9-17)25(26)13-19(29)14-25/h3-12,19,29H,2,13-15,26H2,1H3
  • Key:BPHCAPAOSHZYJY-UHFFFAOYSA-N

Engasertib is an investigational new drug that is being evaluated by Vaderis Therapeutics for the treatment of hereditary haemorrhagic telangiectasia. It acts as a c-akt protein inhibitor.

References

  1. ↑ "Engasertib - Vaderis Therapeutics". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Al-Samkari H, Hessels J, Riera-Mestre A, Dupuis-Girod S, Van Zele T, Gómez Del Olmo V, et al. (November 2025). "Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia". The New England Journal of Medicine. 393 (21): 2131–2141. doi:10.1056/NEJMoa2504411. PMID 41297007.
  3. ↑ Al-Samkari H, Picard D, Mager HJ (February 2026). "Engasertib in Hereditary Hemorrhagic Telangiectasia. Reply". The New England Journal of Medicine. 394 (8): 825–826. doi:10.1056/NEJMc2518633. PMID 41707157.
  4. ↑ Liang D, Lin Y, He L (February 2026). "Engasertib in Hereditary Hemorrhagic Telangiectasia". The New England Journal of Medicine. 394 (8): 825. doi:10.1056/NEJMc2518633. PMID 41707156.